Trials / Recruiting
RecruitingNCT07291076
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 129 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pumitamig | Specified dose on specified days |
| DRUG | Ipilimumab | Specified dose on specified days |
| DRUG | Atezolizumab | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
Timeline
- Start date
- 2026-03-16
- Primary completion
- 2029-10-15
- Completion
- 2031-10-14
- First posted
- 2025-12-18
- Last updated
- 2026-04-14
Locations
46 sites across 13 countries: United States, Australia, Chile, China, France, Germany, Italy, Poland, Singapore, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07291076. Inclusion in this directory is not an endorsement.